Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

8.355 +0.385 (+4.83%)
Streaming Delayed Price Updated: 2:29 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Amicus Therapeutics Earnings Preview
 
Via Benzinga
Earnings Scheduled For February 19, 2025
 
Via Benzinga
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
 
Via Benzinga
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
Amicus (FOLD) Q2 Revenue Jumps 22%
Via The Motley Fool
Topics Intellectual Property
Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading
Amicus Therapeutics (FOLD) beats Q2 2025 revenue and EPS estimates, driven by strong growth in Galafold and Pompe disease therapies, sparking a 2.77% pre-market rally. 
Via Chartmill
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
From Amicus Therapeutics, Inc.; Dimerix Limited
Via GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.